Key result
KT3-671 is a potent AT1 subtype-selective nonpeptide angiotensin II receptor antagonist that dose-dependently decreases arterial blood pressure in hypertensive rats.
Population
In vitro models and in vivo models
Design
Preclinical
Follow-up
up to 24 hours
Authors
Loading...
Does not support clinical use; leaves open translation of this AT1 antagonist to human hypertension.
KT3-671 is a potent, orally active, AT1 subtype-selective nonpeptide angiotensin II receptor antagonist with sustained antihypertensive effects in rat models.
Mochizuki et al. (1995) studied Hypertension (preclinical models). KT3-671 was evaluated on Blood pressure reduction and AT1 receptor binding. KT3-671 is a potent AT1 subtype-selective nonpeptide angiotensin II receptor antagonist that dose-dependently decreases arterial blood pressure in hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: